VADS Are Ready For Wider Population Trial After REMATCH, Experts Agree
This article was originally published in The Gray Sheet
Executive Summary
The high complication rate associated with Thoratec's HeartMate VE ventricular assist device (VAD) in the seminal REMATCH trial should not deter investigators from testing VADs as a destination therapy in patients less ill than the REMATCH cohort, panelists agreed at an April 10 symposium on trials of mechanical circulatory support in Washington, DC